482,655 Shares of ARS Pharmaceuticals, Inc. $SPRY Acquired by Landscape Capital Management L.L.C.

Landscape Capital Management L.L.C. purchased a new stake in ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report) during the third quarter, HoldingsChannel.com reports. The firm purchased 482,655 shares of the company’s stock, valued at approximately $2,080,000.

Other large investors have also recently bought and sold shares of the company. USAdvisors Wealth Management LLC bought a new position in ARS Pharmaceuticals in the 3rd quarter valued at about $43,000. StoneX Group Inc. bought a new stake in shares of ARS Pharmaceuticals during the third quarter worth approximately $44,000. Global Retirement Partners LLC boosted its holdings in shares of ARS Pharmaceuticals by 938.8% during the third quarter. Global Retirement Partners LLC now owns 10,284 shares of the company’s stock worth $44,000 after acquiring an additional 9,294 shares during the period. Inscription Capital LLC acquired a new position in shares of ARS Pharmaceuticals in the third quarter valued at approximately $56,000. Finally, Bessemer Group Inc. grew its position in shares of ARS Pharmaceuticals by 3,102.1% in the first quarter. Bessemer Group Inc. now owns 7,525 shares of the company’s stock valued at $61,000 after purchasing an additional 7,290 shares during the last quarter. 68.16% of the stock is owned by institutional investors.

ARS Pharmaceuticals Stock Up 1.1%

NASDAQ SPRY opened at $3.69 on Thursday. The business has a fifty day moving average price of $3.97 and a two-hundred day moving average price of $6.95. The company has a debt-to-equity ratio of 13.72, a current ratio of 3.25 and a quick ratio of 3.07. ARS Pharmaceuticals, Inc. has a fifty-two week low of $2.44 and a fifty-two week high of $13.15. The stock has a market capitalization of $370.95 million, a PE ratio of -1.83 and a beta of 0.98.

ARS Pharmaceuticals (NASDAQ:SPRY – Get Free Report) last issued its earnings results on Thursday, November 5th. The company reported ($0.36) EPS for the quarter, missing the consensus estimate of ($0.30) by ($0.06). The business had revenue of $37.71 million for the quarter, compared to analyst estimates of $41.99 million. ARS Pharmaceuticals had a negative return on equity of 453.93% and a negative net margin of 163.64%. Equities analysts expect that ARS Pharmaceuticals, Inc. will post -1.90 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

SPRY has been the topic of a number of recent research reports. Weiss Ratings upgraded ARS Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Monday, November 9th. Leerink Partners set a $15.00 price objective on ARS Pharmaceuticals in a report on Tuesday, September 8th. Finally, Raymond James Financial lowered ARS Pharmaceuticals from a “strong-buy” rating to an “outperform” rating in a report on Friday, November 6th. Four analysts have rated the stock with a Buy rating, one has issued a Hold rating and one has given a Sell rating to the stock. According to MarketBeat, ARS Pharmaceuticals presently has a consensus rating of “Moderate Buy” and an average target price of $23.33.

View Our Latest Report on ARS Pharmaceuticals

ARS Pharmaceuticals Company Profile

(Free Report)

ARS Pharmaceuticals, Inc. is a biopharmaceutical company focused on developing needle-free treatments for severe allergic reactions. Its lead product, neffy (epinephrine nasal spray), is designed to provide an alternative to injectable epinephrine for emergency treatment of allergic reactions, including anaphylaxis. The U.S. Food and Drug Administration approved neffy in 2024. The product delivers epinephrine through the nose, addressing the need for a treatment that may be easier to carry and use than an auto-injector.

Featured Articles

Want to see what other hedge funds are holding SPRY? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for ARS Pharmaceuticals, Inc. (NASDAQ:SPRY – Free Report).

Institutional Ownership by Quarter for ARS Pharmaceuticals (NASDAQ:SPRY)

Receive News & Ratings for ARS Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for ARS Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.